BR112018004400A2 - composições de vacina vlp estabilizadas - Google Patents

composições de vacina vlp estabilizadas

Info

Publication number
BR112018004400A2
BR112018004400A2 BR112018004400A BR112018004400A BR112018004400A2 BR 112018004400 A2 BR112018004400 A2 BR 112018004400A2 BR 112018004400 A BR112018004400 A BR 112018004400A BR 112018004400 A BR112018004400 A BR 112018004400A BR 112018004400 A2 BR112018004400 A2 BR 112018004400A2
Authority
BR
Brazil
Prior art keywords
vaccines
vaccine compositions
vlp vaccine
vaccine
directed
Prior art date
Application number
BR112018004400A
Other languages
English (en)
Inventor
V Kapre Subhash
Original Assignee
Inventprise Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inventprise Llc filed Critical Inventprise Llc
Publication of BR112018004400A2 publication Critical patent/BR112018004400A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10141—Use of virus, viral particle or viral elements as a vector
    • C12N2730/10142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

a invenção é dirigida a composições e métodos para a estabilização de vacinas virais e bacterianas. as vacinas da invenção estão contidas em vlps com agentes estabilizadores, tais como, por exemplo, álcoois de açúcar (por exemplo, sorbitol) e gelatinas degradadas. de preferência, a gelatina tem um peso molecular médio de 10 000 quilodaltons ou menos. estas vacinas têm uma termoestabilidade substancialmente melhorada, bem como a estabilidade a longo prazo. a invenção também é dirigida a fabricação de uma vacina ou a invenção e métodos para a administração de uma vacina da invenção a pacientes.
BR112018004400A 2015-09-04 2016-09-06 composições de vacina vlp estabilizadas BR112018004400A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562214526P 2015-09-04 2015-09-04
PCT/US2016/050375 WO2017041083A1 (en) 2015-09-04 2016-09-06 Vlp stabilized vaccine compositions

Publications (1)

Publication Number Publication Date
BR112018004400A2 true BR112018004400A2 (pt) 2018-12-04

Family

ID=58188631

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018004400A BR112018004400A2 (pt) 2015-09-04 2016-09-06 composições de vacina vlp estabilizadas

Country Status (8)

Country Link
US (3) US10758606B2 (pt)
EP (1) EP3344293A4 (pt)
KR (2) KR20180041237A (pt)
CN (1) CN108472357A (pt)
BR (1) BR112018004400A2 (pt)
PH (1) PH12018500458A1 (pt)
WO (1) WO2017041083A1 (pt)
ZA (1) ZA201801496B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3087188A1 (en) 2013-12-23 2016-11-02 Theravectys Lyophilized lentiviral vector particles, compositions and methods
CN108025053A (zh) * 2015-04-16 2018-05-11 创赏有限公司 百日咳杆菌免疫原性的疫苗组合物
MY177587A (en) 2015-09-10 2020-09-22 Inventprise Llc Multivalent vlp conjugates
EP4282955A1 (en) * 2021-01-19 2023-11-29 Nitta Gelatin Inc. Virus stabilizer, gelatin hydrolysate for virus stabilizer, and virus-containing composition
CN114569717B (zh) * 2022-03-05 2023-11-14 广西博生生物科技有限公司 一种抗hpv病毒的卵黄免疫球蛋白凝胶及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL183781B1 (pl) * 1994-05-16 2002-07-31 Merck & Co Inc Sposób wytwarzania szczepionki przeciwko ludzkiemu wirusowi brodawczaków
US6290967B1 (en) * 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
CU22871A1 (es) 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
EP1135408B1 (en) * 1998-12-04 2011-09-21 Biogen Idec MA Inc. Hbv core antigen particles with multiple immunogenic components attached via peptide ligands
US6992172B1 (en) * 1999-11-12 2006-01-31 Fibrogen, Inc. Recombinant gelatins
DE60211889T2 (de) 2001-04-23 2007-06-14 Yokowo Co., Ltd. Breitbandantenne für die drahtlose kommunikation
ES2280809T3 (es) * 2002-11-01 2007-09-16 Glaxosmithkline Biologicals S.A. Composicion inmunogenica.
JP5135220B2 (ja) * 2005-09-01 2013-02-06 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 血清群ｃ髄膜炎菌を含む複数ワクチン接種
US20070184068A1 (en) 2005-12-14 2007-08-09 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
CN102014873A (zh) * 2008-02-25 2011-04-13 诺瓦瓦克斯股份有限公司 糖玻璃化的病毒样颗粒
BRPI0915076A2 (pt) * 2008-06-09 2017-03-14 Bharat Biotech Int Ltd composições de vacina, composição imunogênica, método para expressão dos antígenos quiméricos de hpv-hbsag supramencionados, composição farmacêutica, método para ocasionar resposta de anticorpo protetor para composição antigênica e/ou resposta de célula t citotóxica, uso das formulações antigênicas supramencionadas.
US20110243988A1 (en) * 2009-10-01 2011-10-06 Aridis Pharmaceuticals Methods and Compositions for Stabilization of a Virus Vaccine
WO2011079260A2 (en) * 2009-12-23 2011-06-30 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Stabilized virus like particles having enhanced mucosal immunogenicity
WO2012023033A2 (en) 2010-08-18 2012-02-23 Purdue Pharma L.P. Improved peptide immunogens
EP3057612B1 (en) * 2013-10-16 2020-05-06 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
WO2016022916A2 (en) 2014-08-08 2016-02-11 U.S. Army Medical Research Institute Of Infectious Diseases Department Of The Army Thermostable, chromatographically purified nano-vlp vaccine
CN104312986A (zh) * 2014-10-17 2015-01-28 中国人民解放军第四军医大学 嵌合hcv中和表位的hbv s抗原病毒样颗粒及其制备方法和应用

Also Published As

Publication number Publication date
US20170065704A1 (en) 2017-03-09
KR20180041237A (ko) 2018-04-23
ZA201801496B (en) 2019-01-30
US20210069318A1 (en) 2021-03-11
KR20200000497A (ko) 2020-01-02
EP3344293A4 (en) 2019-01-16
US11878054B2 (en) 2024-01-23
US20240148852A1 (en) 2024-05-09
US10758606B2 (en) 2020-09-01
WO2017041083A1 (en) 2017-03-09
CN108472357A (zh) 2018-08-31
EP3344293A1 (en) 2018-07-11
PH12018500458A1 (en) 2018-09-10

Similar Documents

Publication Publication Date Title
BR112018004400A2 (pt) composições de vacina vlp estabilizadas
MX2022001755A (es) Compuestos de dinucleotidos ciclicos y metodos de uso.
CY1120681T1 (el) Υγρη φαρμακευτικη συνθεση
CY1124493T1 (el) Υγρη φαρμακευτικη συνθεση
MX2016003419A (es) Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico.
BR112018006922A2 (pt) composições farmacêuticas estabilizantes de camptotecina
CY1122793T1 (el) Χλωριουχο αλας του tat-nr2b9c
AU2014375637A1 (en) Formula of neuregulin preparation
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
PH12018500690A1 (en) Novel insulin analogs and use thereof
BR112019009131A2 (pt) vacina contra o parvovírus suíno, o vírus da síndrome respiratória e reprodutiva dos suínos e métodos de produção das mesmas
MX2017002803A (es) Coronavirus bovino atenuado y vacunas relacionadas.
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
BR112017005821A2 (pt) formulação aquosa, método para a preparação de uma formulação aquosa, conjunto, método para a preparação de uma composição farmacêutica, composição farmacêutica e método para quimicamente estabilizar uma formulação aquosa
PH12016501519A1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
BR112018068342A2 (pt) vacina de vírus zika vivo atenuado
MX2016014937A (es) Composiciones para el cuidado bucal que tienen estabilidad mejorada.
WO2018091729A3 (en) Aqueous pharmaceutical formulations
PH12016501877A1 (en) Lypophilized factor ix formulations
EA033306B1 (ru) Стабилизированный раствор на основе активных веществ, способ получения стабилизированного раствора активных веществ, фармацевтическая композиция на основе стабилизированного раствора активных веществ (два варианта)
DOP2017000116A (es) Composiciones de acción prolongada de combinación y procedimientos para hepatitis c
MX2018011016A (es) Formulaciones estables para liofilizar particulas terapeuticas.
PH12020500022A1 (en) Salt of (ss)-adenosyl methionine with inositol hexaphosphate, and process for the preparation thereof
EA202090236A1 (ru) Иммуногенные композиции senecavirus a и способы с ними

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25D Requested change of name of applicant approved

Owner name: INVENTPRISE, INC. (US)